Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Osteoporosis 9Breast Neoplasms 6Bone Diseases, Metabolic 5Prostatic Neoplasms 4Triple Negative Breast Neoplasms 1Prostatic Hyperplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteoporosis, Postmenopausal 1Lymphoma 1Lung Neoplasms 1Leukemia 1Esophageal Neoplasms 1Dwarfism, Pituitary 1Carcinoma, Squamous Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Adenocarcinoma 1

Interventions

pembrolizumab 161Carboplatin 145Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 38sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Risedronic Acid × Clear all
NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Harbin Medical University

Phase 2 Active not recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡